Spots Global Cancer Trial Database for neoplasms, breast
Every month we try and update this database with for neoplasms, breast cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Treatment With Pazopanib for Neoadjuvant Breast Cancer | NCT00849472 | Neoplasms, Brea... | doxorubicin + c... paclitaxel + pa... surgery pazopanib monot... | 18 Years - | GlaxoSmithKline | |
| Pre- Versus Postoperative Accelerated Partial Breast Irradiation | NCT02913729 | Breast Cancer Cancer of the B... Neoplasms, Brea... | partial breast ... | 51 Years - | The Netherlands Cancer Institute | |
| Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study | NCT00553358 | Neoplasms, Brea... | Lapatinib Trastuzumab Paclitaxel | 18 Years - | Novartis | |
| A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients | NCT00821054 | Neoplasms, Brea... | Lapatinib | 18 Years - 65 Years | GlaxoSmithKline | |
| Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer | NCT00374322 | Neoplasms, Brea... | lapatinib placebo | 18 Years - | GlaxoSmithKline | |
| A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer | NCT03583944 | Breast Neoplasm... | Eribulin Mesyla... | 18 Years - | Eisai Inc. | |
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | NCT04521686 | Cholangiocarcin... Chondrosarcoma Glioma Any Solid Tumor | LY3410738 Gemcitabine Cisplatin Durvalumab | 18 Years - | Eli Lilly and Company | |
| Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer | NCT00111787 | Neoplasms, Brea... | Lapatinib Paclitaxel | 18 Years - | GlaxoSmithKline | |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | NCT03157128 | Non-Small Cell ... Medullary Thyro... Colon Cancer Any Solid Tumor | LOXO-292 | 12 Years - | Eli Lilly and Company | |
| Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients | NCT01782651 | Neoplasms, Brea... | Lapatinib plus ... | 18 Years - | GlaxoSmithKline | |
| Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin. | NCT00051103 | Metastatic Brea... Neoplasms, Brea... | Investigational... | 18 Years - | GlaxoSmithKline | |
| A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer | NCT00058526 | Neoplasms, Brea... | Immunotherapeut... | 40 Years - 70 Years | GlaxoSmithKline | |
| Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer | NCT01271738 | Breast Neoplasm... Breast Cancer Breast Tumors Cancer of Breas... Cancer of the B... Human Mammary C... Neoplasms, Brea... | Remove tumor on... Removal of tumo... | 18 Years - | Emory University | |
| Early Rehabilitation for Breast Cancer - A Randomized Control Trial | NCT04777786 | Neoplasms, Brea... | Physical Therap... | 18 Years - | University of South Carolina | |
| A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer | NCT03583944 | Breast Neoplasm... | Eribulin Mesyla... | 18 Years - | Eisai Inc. | |
| Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 | NCT00281658 | Neoplasms, Brea... | Lapatinib (GW57... Paclitaxel infu... Placebo | 18 Years - | Novartis | |
| Study of ESG401 in Adults With Solid Tumors | NCT04892342 | Neoplasms, Brea... Neoplasms, Lung Neoplasms,Color... Neoplasms, Blad... Neoplasm of Sto... Neoplasms,Ovari... | ESG401 | 18 Years - 75 Years | Shanghai Escugen Biotechnology Co., Ltd | |
| A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib | NCT00996762 | Neoplasms, Brea... | lapatinib | 18 Years - | GlaxoSmithKline | |
| Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin. | NCT00051103 | Metastatic Brea... Neoplasms, Brea... | Investigational... | 18 Years - | GlaxoSmithKline | |
| A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients | NCT01905592 | Neoplasms, Brea... Carcinoma of Br... Human Epidermal... BRCA1 Gene Muta... BRCA2 Gene Muta... Ovarian Neoplas... | niraparib Physician's cho... | 18 Years - | Tesaro, Inc. | |
| Rollover Study Of Lapatinib In Cancer Patients | NCT00169533 | Neoplasms, Brea... | GW572016 oral t... | 18 Years - | GlaxoSmithKline | |
| Study Of Ispinesib In Subjects With Breast Cancer | NCT00089973 | Neoplasms, Brea... | Ispinesib | 18 Years - | GlaxoSmithKline | |
| Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | NCT00075270 | Neoplasms, Brea... | Paclitaxel GW572016 (Lapat... | 18 Years - | GlaxoSmithKline | |
| Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer | NCT01498588 | Breast Neoplasm... Breast Cancer Breast Tumors Cancer of the B... Neoplasms, Brea... Tumors, Breast | Eribulin Doxorubicin Cyclophosphamid... Pegfilgrastim | 18 Years - | Emory University | |
| A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | NCT01160211 | Neoplasms, Brea... | lapatinib trastuzumab Aromatase inhib... lapatinib | 18 Years - | Novartis | |
| Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer | NCT01476111 | Neoplasms, Brea... | 18 Years - | GlaxoSmithKline | ||
| Lapatinib in Combination With Vinorelbine | NCT01013740 | Cancer | Vinorelbine Lapatinib Capecitabine | 18 Years - | Novartis | |
| A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors | NCT00722293 | Neoplasms, Brea... | Doxorubicin Pazopanib (GW78... Epirubicin | 18 Years - | GlaxoSmithKline | |
| Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy | NCT00661531 | Breast Cancer Cancer of the B... Neoplasms, Brea... | Estrace Anastrozole | 18 Years - | Georgetown University | |
| Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | NCT00558103 | Neoplasms, Brea... | lapatinib Pazopanib | 18 Years - | GlaxoSmithKline | |
| Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | NCT04521686 | Cholangiocarcin... Chondrosarcoma Glioma Any Solid Tumor | LY3410738 Gemcitabine Cisplatin Durvalumab | 18 Years - | Eli Lilly and Company | |
| Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer | NCT01220128 | Neoplasms, Brea... | GSK Biologicals... Placebo Aromatase inhib... 5-Fluorouracil Carboplatin AUC Cyclophosphamid... Docetaxel Doxorubicin Epirubicin Paclitaxel Trastuzumab | 18 Years - | GlaxoSmithKline | |
| Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer | NCT00263588 | Neoplasms, Brea... | lapatinib | 18 Years - | Novartis | |
| A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer | NCT00849329 | Neoplasms, Brea... | lapatinib lapatinib plus ... | 18 Years - 65 Years | GlaxoSmithKline | |
| Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer | NCT00359190 | Neoplasms, Brea... | lapatinib | 18 Years - | GlaxoSmithKline | |
| Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer | NCT00422903 | Neoplasms, Brea... | lapatinib letrozole placebo | 18 Years - 80 Years | GlaxoSmithKline | |
| Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB) | NCT00388076 | Neoplasms, Brea... | Pazopanib Lapatinib paclitaxel carboplatin | 18 Years - | GlaxoSmithKline | |
| Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer | NCT00356811 | Neoplasms, Brea... | Lapatinib oral ... Paclitaxel infu... | 18 Years - | GlaxoSmithKline | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. | NCT00524303 | Neoplasms, Brea... | Trastuzumab Paclitaxel FEC75 Lapatinib | 18 Years - | GlaxoSmithKline | |
| Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | NCT00075270 | Neoplasms, Brea... | Paclitaxel GW572016 (Lapat... | 18 Years - | GlaxoSmithKline | |
| A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer | NCT01137994 | Neoplasms, Brea... | Lapatinib Trastuzumab Docetaxel Paclitaxel Vinorelbine | 18 Years - | GlaxoSmithKline | |
| Single Dose Partial Breast Radiotherapy | NCT00944528 | Breast Cancer | Radiosurgery | 55 Years - 80 Years | Duke University | |
| A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib | NCT00996762 | Neoplasms, Brea... | lapatinib | 18 Years - | GlaxoSmithKline | |
| Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer | NCT00650910 | Neoplasms, Brea... | lapatinib Digoxin | 18 Years - 65 Years | GlaxoSmithKline | |
| Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer | NCT00089999 | Neoplasms, Brea... | Lapatinib | 18 Years - | GlaxoSmithKline | |
| Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer. | NCT00367471 | Neoplasms, Brea... | lapatinib carboplatin trastuzumab paclitaxel | 18 Years - | Novartis | |
| GW572016 For Treatment Of Refractory Metastatic Breast Cancer | NCT00062686 | Neoplasms, Brea... | GW572016 | 18 Years - | GlaxoSmithKline | |
| Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 | NCT00281658 | Neoplasms, Brea... | Lapatinib (GW57... Paclitaxel infu... Placebo | 18 Years - | Novartis | |
| Lapatinib in Combination With Vinorelbine | NCT01013740 | Cancer | Vinorelbine Lapatinib Capecitabine | 18 Years - | Novartis | |
| Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer | NCT00422903 | Neoplasms, Brea... | lapatinib letrozole placebo | 18 Years - 80 Years | GlaxoSmithKline | |
| Pre- Versus Postoperative Accelerated Partial Breast Irradiation | NCT02913729 | Breast Cancer Cancer of the B... Neoplasms, Brea... | partial breast ... | 51 Years - | The Netherlands Cancer Institute | |
| GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer | NCT00251433 | Neoplasms, Brea... | lapatinib, doce... | 18 Years - | Novartis | |
| Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. | NCT00524303 | Neoplasms, Brea... | Trastuzumab Paclitaxel FEC75 Lapatinib | 18 Years - | GlaxoSmithKline | |
| Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer | NCT02063893 | Neoplasms, Brea... | 30 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | ||
| A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer | NCT03583944 | Breast Neoplasm... | Eribulin Mesyla... | 18 Years - | Eisai Inc. | |
| Early Rehabilitation for Breast Cancer - A Randomized Control Trial | NCT04777786 | Neoplasms, Brea... | Physical Therap... | 18 Years - | University of South Carolina | |
| Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer | NCT00140738 | Neoplasms, Brea... | GSK Biologicals... | 18 Years - | GlaxoSmithKline | |
| GW572016 In Patients With Advanced Or Metastatic Breast Cancer | NCT00462956 | Neoplasms, Brea... | Tykerb | 20 Years - 40 Years | GlaxoSmithKline | |
| EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer | NCT00338247 | Neoplasms, Brea... | lapatinib + cap... | 18 Years - | Novartis | |
| A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer | NCT00849329 | Neoplasms, Brea... | lapatinib lapatinib plus ... | 18 Years - 65 Years | GlaxoSmithKline | |
| Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer | NCT02213042 | Neoplasms, Brea... | Lapatinib Trastuzumab Aromatase Inhib... | 18 Years - | Novartis | |
| Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer. | NCT00367471 | Neoplasms, Brea... | lapatinib carboplatin trastuzumab paclitaxel | 18 Years - | Novartis | |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors | NCT03899792 | Medullary Thyro... Infantile Myofi... Infantile Fibro... Papillary Thyro... Soft Tissue Sar... | LOXO-292 | 6 Months - 21 Years | Eli Lilly and Company | |
| ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib | NCT00272987 | Neoplasms, Brea... | lapatinib paclitaxel trastuzumab | 18 Years - | Novartis | |
| Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer | NCT01271738 | Breast Neoplasm... Breast Cancer Breast Tumors Cancer of Breas... Cancer of the B... Human Mammary C... Neoplasms, Brea... | Remove tumor on... Removal of tumo... | 18 Years - | Emory University | |
| GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer | NCT00320411 | Neoplasms, Brea... | lapatinib | 20 Years - 74 Years | GlaxoSmithKline | |
| GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer | NCT00371488 | Neoplasms, Brea... | GW572016 oral t... | 20 Years - 74 Years | GlaxoSmithKline | |
| Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects | NCT00709618 | Neoplasms, Brea... | Lapatinib, Vino... | 18 Years - | GlaxoSmithKline | |
| Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer | NCT00359190 | Neoplasms, Brea... | lapatinib | 18 Years - | GlaxoSmithKline | |
| Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer | NCT00374322 | Neoplasms, Brea... | lapatinib placebo | 18 Years - | GlaxoSmithKline | |
| Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer | NCT00089999 | Neoplasms, Brea... | Lapatinib | 18 Years - | GlaxoSmithKline | |
| Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer | NCT02063893 | Neoplasms, Brea... | 30 Years - 75 Years | Fuda Cancer Hospital, Guangzhou | ||
| Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | NCT00558103 | Neoplasms, Brea... | lapatinib Pazopanib | 18 Years - | GlaxoSmithKline | |
| Brain Metastases In ErbB2-Positive Breast Cancer | NCT00437073 | Neoplasms, Brea... | capecitabine topotecan lapatinib | 18 Years - | GlaxoSmithKline | |
| GW572016 For Treatment Of Refractory Metastatic Breast Cancer | NCT00062686 | Neoplasms, Brea... | GW572016 | 18 Years - | GlaxoSmithKline | |
| A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors | NCT00722293 | Neoplasms, Brea... | Doxorubicin Pazopanib (GW78... Epirubicin | 18 Years - | GlaxoSmithKline | |
| Effects Of GW572016 In Combination With Docetaxel (TAXOTERE) | NCT00148902 | Neoplasms, Brea... | lapatinib docetaxel | 18 Years - | GlaxoSmithKline | |
| Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study | NCT00553358 | Neoplasms, Brea... | Lapatinib Trastuzumab Paclitaxel | 18 Years - | Novartis | |
| Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer | NCT00140738 | Neoplasms, Brea... | GSK Biologicals... | 18 Years - | GlaxoSmithKline |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
